CD123 CAR-T cells
Phase 1Cell therapy
CD123 CAR-T cells is one of 79 biologic programs targeting Leukemia. It is currently in Phase 1.
3
Indications
4
Total Trials
1
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Nexavar
BayerPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Astplayer
AAstex Pharmaceuticals, Inc.
Phase 3
Caspofungin Acetate
Merck & Co.Phase 3
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Phase 3
Sapacitabine
CCyclacel Pharmaceuticals, Inc.
Phase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
ALL-Trans Retinoid Acid
UUniversity of Ulm
Phase 3
Consolidation Chemotherapy
SShenzhen People's Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia2 trials
Blastic Plasmacytoid Dendritic Cell Neoplasm1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD123 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details